BT cloud service aims to accelerate drug discovery

Published: 31-May-2012

BT for Life Sciences R&D is being developed to become a secure and segregated platform for pharmaceutical, biotech, medical device and diagnostic companies. It will allow them to construct in silico workflows and data pipelines to identify new drug candidates

You need to be a subscriber to read this article.
Click here to find out more.

UK communications services and solutions supplier BT is launching a cloud service to allow collaboration within the life sciences industry

UK-based BT, a leading global provider of communications services and solutions, has launched BT for Life Sciences R&D, a cloud service designed to enable collaboration within the life sciences industry for increased r&d productivity while allowing customers to comply with the industry’s stringent security, regulatory and compliance requirements.

BT for Life Sciences R&D is being developed to become a secure and segregated platform for scientists in pharmaceutical, biotech, medical device and diagnostics companies as well as in academia and government. It will allow them to construct and orchestrate in silico workflows and data pipelines to identify new pharmaceutical targets and drug candidates.

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.

You may also like